In a study investigating the potential of bexarotene in atherosclerosis, the mRNA levels of both NPC1L1 and ABCA1 were found to be reduced in the duodenum and jejunum of bexarotene-treated mice, supporting our findings. Here, NPC1L1 is linked to atherosclerosis.